Alternating chemo drugs for older or frailer adults with new AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two chemotherapy regimens given in turns for people with newly diagnosed acute myeloid leukemia (AML) who cannot have standard intensive chemotherapy. The goal is to find a gentler but effective treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with AML (a type of blood cancer) for the first time and have not had any treatment yet.
- You are 60 years or older, or between 18 and 59 but not healthy enough for strong chemotherapy due to heart, lung, kidney, or liver problems, or a low performance status.
- You do not have a specific type of AML called acute promyelocytic leukemia or a FLT3-ITD gene change.
- You have not had any other active cancer (except minor skin cancers) in the last 2 years.
- You can swallow pills and do not have severe gut problems that affect absorption.
- You are not pregnant, breastfeeding, and are willing to use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (venetoclax, azacitidine, chidamide, and CAG chemotherapy) to treat newly diagnosed acute myeloid leukemia (AML—a blood cancer) in adults aged 60–75. The goal is to see if this combination helps patients live longer and feel better.
This trial compares two different combinations of chemotherapy drugs for older adults (ages 55-75) with newly diagnosed acute myeloid leukemia (AML) who are otherwise healthy enough to tolerate intensive treatment. The goal is to see which combination is more effective and has fewer side effects.
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
This trial compares four different combinations of targeted therapy and chemotherapy for people with newly diagnosed AML who cannot have standard intensive chemo. The goal is to see which combination works best safely.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
This clinical trial tests a combination of three drugs: a liposomal form of mitoxantrone (a type of chemotherapy), cytarabine (another chemo drug), and venetoclax (a targeted therapy). The goal is to see if this combination is safe and works well for older adults (ages 60-70) who have just been diagnosed with AML and cannot have standard intensive chemotherapy.
Hear when a new Newly Diagnosed Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.